Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy
Scientific Reports · 2024
DOI: 10.1038/s41598-024-78581-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Hyun Jung Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, …. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Apoptosis, Indomethacin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SNUH Research Fund, Korean government (MSIT).
Abstract (Originalsprache)
As the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and treatment strategies are crucial. We assessed the effect of tegoprazan on NSAID-induced enteropathy. Human epithelial cells (HIEC-6, HT-29, and Caco-2) were treated with indomethacin and tegoprazan. Cell viability, expression levels of tight-junction proteins, levels of proinflammatory cytokines, and apoptosis were assessed by conducting MTT assays, RT-PCR, western blotting, and immunofluorescence staining, respectively. Tegoprazan significantly ameliorated the inhibition of cell proliferation induced by indomethacin. Tegoprazan also mitigated the suppression of occludin and ZO-1 expression by indomethacin, thereby restoring intestinal permeability. Additionally, tegoprazan reversed the indomethacin-induced elevation of the levels of proinflammatory cytokines and the rate of apoptosis of small intestinal epithelial cells. Our findings indicate that tegoprazan exerts a protective effect against NSAID-induced injury to small intestinal epithelial cells. The effect involves enhancement of the expression levels of tight junction proteins and the suppression of inflammation and apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea. guswjd80@snu.ac.kr.
- BK21 Graduate Program, Department of Biomedical Sciences, Department of Anatomy, Korea University College of Medicine, Seoul, Korea.
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
Förderung
- SNUH Research Fund
- Korean government (MSIT)
Zitieren
APA
Lee, H. J., Moon, J. W., Koh, S. J., Im, J. P., Kim, B. G., & Kim, J. S. (2024). Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy. Scientific Reports. https://doi.org/10.1038/s41598-024-78581-2
Vancouver
Lee HJ, Moon JW, Koh SJ, Im JP, Kim BG, Kim JS. Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy. Scientific Reports. 2024. doi:10.1038/s41598-024-78581-2
BibTeX
@article{Lee2024,
author = {Lee, Hyun Jung and Moon, Ji Wook and Koh, Seong-Joon and Im, Jong Pil and Kim, Byeong Gwan and Kim, Joo Sung},
title = {Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-78581-2}
}
EUVIMED